Oriva: Targeting the endometriosis trifecta

Oriva Therapeutics is building a women’s health pipeline by repurposing cancer assets to target chronic gynecologic diseases, and betting that shared biology between malignant tumors and benign proliferative disorders can unlock first-in-class, disease-modifying therapies.

CEO and CMO Agnès Arbat told BioCentury Oriva’s approach is part of a broader shift in next-generation endometriosis therapeutics toward non-hormonal mechanisms. The current endometriosis pipeline is dominated by hormonal approaches, particularly therapies that suppress disease-promoting estrogen production by targeting upstream gonadotropin-releasing hormone, or GnRH. These therapies can cause menopause-like side effects, including an increased risk of osteoporosis...